- Date 28 May 2025
- Documents : 3
- History
- (Restricted access link)
Listen
TECENTRIQ (atezolizumab) - Advanced NSCLC
Opinions on drugs -
Posted on
Jun 18 2025
Reason for request
Inclusion on list
Summary of opinion
Unfavourable opinion for reimbursement of TECENTRIQ as monotherapy in “the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy (see section 5.1 of the Summary of Product Characteristics (SPC) for selection criteria).”
Clinical Benefit
| Insufficient |
The clinical benefit of TECENTRIQ (atezolizumab) (TECENTRIQ 840 mg and 1,200 mg concentrate for solution for infusion and TECENTRIQ 1,875 mg solution for injection) is insufficient in the MA indication to justify public funding in view of the available alternatives. |
Clinical Added Value
| Not applicable |
English version
Contact Us
Évaluation des médicaments
